HEALTHSEMAFOR
Medical tourism boom in China
China is becoming a hub for medical tourism, offering procedures like CAR-T cancer immunotherapy at significantly lower costs than in the US. The country has established a special medical tourism zone in Hainan and relaxed visa rules to attract international patients. Licensing deals between Chinese biopharma companies and global drugmakers reached $137 billion last year, driven by cost advantages in drug development.
Mentioned
Related Signal
Adjacent reporting
- Why are foreigners flocking to China for health care?
- China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
- Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
- China, South Korea boost commercial flights as tourism increases between the 2 countries